Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to 0.95.
- Keros Therapeutics' Equity Ratio rose 297.71% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year increase of 297.71%. This contributed to the annual value of 0.93 for FY2024, which is 336.43% up from last year.
- Latest data reveals that Keros Therapeutics reported Equity Ratio of 0.95 as of Q3 2025, which was up 297.71% from 0.93 recorded in Q2 2025.
- Keros Therapeutics' 5-year Equity Ratio high stood at 0.97 for Q2 2021, and its period low was 0.9 during Q4 2023.
- Its 5-year average for Equity Ratio is 0.93, with a median of 0.93 in 2022.
- Per our database at Business Quant, Keros Therapeutics' Equity Ratio surged by 33481.7% in 2021 and then crashed by 507.86% in 2022.
- Quarter analysis of 5 years shows Keros Therapeutics' Equity Ratio stood at 0.95 in 2021, then fell by 5.08% to 0.9 in 2022, then decreased by 0.72% to 0.9 in 2023, then increased by 3.36% to 0.93 in 2024, then increased by 2.07% to 0.95 in 2025.
- Its last three reported values are 0.95 in Q3 2025, 0.93 for Q2 2025, and 0.93 during Q1 2025.